Evoke Pharma (EVOK) said Monday that a study showed that its nasal spray, Gimoti, used to treat patients with diabetic gastroparesis who were concurrently using GLP-1, showed reduced healthcare resource utilization compared with oral Metoclopramide.
The study showed that all-cause emergency department visits decreased by 55%, while diabetic gastroparesis-related emergency department visits reduced by 28% in patients with a prior GLP-1 history, the company said.
It added that all-cause and diabetic gastroparesis-related emergency departments were 91% and 89% lower, respectively, in patients taking GLP-1.
Shares of the drug developer more than doubled in premarket activity.
Price: 11.50, Change: +6.37, Percent Change: +124.17
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。